GlaxoSmithKline and Sanofi said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s effectiveness in older people.The companies said early trials showed the vaccine produced an “insufficient” immune response in older adults, demonstrating the need to refine the product so it protects people of all ages.
London-based GSK and Paris-based Sanofi, now expect the vaccine to be available in the fourth quarter of 2021.“The results of the study are not as we hoped,” Roger Connor, president of GSK Vaccines, said in a statement.